SI3471780T1 - Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom - Google Patents
Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptomInfo
- Publication number
- SI3471780T1 SI3471780T1 SI201730553T SI201730553T SI3471780T1 SI 3471780 T1 SI3471780 T1 SI 3471780T1 SI 201730553 T SI201730553 T SI 201730553T SI 201730553 T SI201730553 T SI 201730553T SI 3471780 T1 SI3471780 T1 SI 3471780T1
- Authority
- SI
- Slovenia
- Prior art keywords
- aflibercept
- aav2
- sdm
- version
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351234P | 2016-06-16 | 2016-06-16 | |
| PCT/US2017/038003 WO2017218974A2 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
| EP17814223.8A EP3471780B1 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3471780T1 true SI3471780T1 (sl) | 2021-03-31 |
Family
ID=60663653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730553T SI3471780T1 (sl) | 2016-06-16 | 2017-06-16 | Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom |
| SI201731629T SI3795181T1 (sl) | 2016-06-16 | 2017-06-16 | Zdravljenje amd z uporabo variante aav2 z afliberceptom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731629T SI3795181T1 (sl) | 2016-06-16 | 2017-06-16 | Zdravljenje amd z uporabo variante aav2 z afliberceptom |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20190151409A1 (https=) |
| EP (3) | EP3471780B1 (https=) |
| JP (5) | JP6814822B2 (https=) |
| KR (2) | KR102218265B1 (https=) |
| CN (2) | CN109641065A (https=) |
| AU (3) | AU2017286673B2 (https=) |
| BR (1) | BR112018076124A2 (https=) |
| CA (1) | CA3027737A1 (https=) |
| CY (1) | CY1123697T1 (https=) |
| DK (2) | DK3471780T3 (https=) |
| ES (2) | ES2840059T3 (https=) |
| FI (1) | FI3795181T3 (https=) |
| HR (2) | HRP20251248T1 (https=) |
| HU (1) | HUE051953T2 (https=) |
| IL (3) | IL279919B2 (https=) |
| LT (2) | LT3471780T (https=) |
| MX (2) | MX391779B (https=) |
| PL (1) | PL3795181T3 (https=) |
| PT (2) | PT3471780T (https=) |
| RS (2) | RS67328B1 (https=) |
| SG (1) | SG11201811232XA (https=) |
| SI (2) | SI3471780T1 (https=) |
| SM (2) | SMT202500400T1 (https=) |
| WO (1) | WO2017218974A2 (https=) |
| ZA (1) | ZA201808538B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| CN111770999A (zh) * | 2017-11-27 | 2020-10-13 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和用于抑制血管生成的应用 |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| US20210154270A1 (en) * | 2018-04-12 | 2021-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| JP7597380B2 (ja) * | 2019-03-04 | 2024-12-10 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与 |
| WO2020219868A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| HRP20260137T1 (hr) * | 2019-09-11 | 2026-03-13 | Adverum Biotechnologies, Inc. | Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept |
| CA3147843A1 (en) * | 2019-09-11 | 2021-03-18 | Mehdi Gasmi | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| TWI819268B (zh) | 2020-01-16 | 2023-10-21 | 詹姆斯 Ｗ 希爾 | 藉由基因轉導改變眼睛顏色 |
| FR3111913A1 (fr) * | 2020-06-30 | 2021-12-31 | Eyevensys | Construction d’adn pour le traitement de pathologies oculaires |
| JP7842082B2 (ja) * | 2020-07-21 | 2026-04-07 | エフティージェン コーポレーション | 眼疾患を処置するための組成物および方法 |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113817775B (zh) * | 2020-08-25 | 2023-02-17 | 南京吉迈生物技术有限公司 | 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用 |
| CA3192736A1 (en) * | 2020-09-03 | 2022-03-10 | University Of Massachusetts | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2021049374A (ja) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | 遊技機 |
| BR112023019056A2 (pt) * | 2021-04-27 | 2024-01-16 | Adverum Biotechnologies Inc | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte |
| AU2023220237A1 (en) | 2022-02-21 | 2024-08-15 | Shanghai Regenelead Therapies Co., Ltd | Vegf-binding molecule and pharmaceutical use thereof |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| TW202508610A (zh) | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| WO2025072688A2 (en) * | 2023-09-27 | 2025-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105755044A (zh) * | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| ES2753135T3 (es) * | 2012-05-07 | 2020-04-07 | Allergan Inc | Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| WO2013188316A1 (en) * | 2012-06-11 | 2013-12-19 | Avalanche Biotechnologies, Inc. | Optical regulation of gene expression in the retina |
| DK4374873T3 (da) * | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| CA2926853C (en) * | 2013-10-18 | 2022-04-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| US11021519B2 (en) * | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
-
2017
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt unknown
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 SM SM20250400T patent/SMT202500400T1/it unknown
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 FI FIEP20196657.9T patent/FI3795181T3/fi active
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 PT PT201966579T patent/PT3795181T/pt unknown
- 2017-06-16 SM SM20210010T patent/SMT202100010T1/it unknown
- 2017-06-16 DK DK20196657.9T patent/DK3795181T3/da active
- 2017-06-16 IL IL279919A patent/IL279919B2/en unknown
- 2017-06-16 RS RS20251055A patent/RS67328B1/sr unknown
- 2017-06-16 HR HRP20251248TT patent/HRP20251248T1/hr unknown
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en not_active Ceased
- 2017-06-16 IL IL314568A patent/IL314568B2/en unknown
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active Active
- 2017-06-16 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2017-06-16 EP EP20196657.9A patent/EP3795181B1/en active Active
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
- 2017-06-16 MX MX2018015512A patent/MX391779B/es unknown
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Ceased
- 2017-06-16 LT LTEP20196657.9T patent/LT3795181T/lt unknown
- 2017-06-16 PL PL20196657.9T patent/PL3795181T3/pl unknown
- 2017-06-16 EP EP25187377.4A patent/EP4671369A3/en active Pending
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 ES ES20196657T patent/ES3049818T3/es active Active
- 2017-06-16 SI SI201731629T patent/SI3795181T1/sl unknown
-
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
-
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
-
2021
- 2021-09-01 AU AU2021225178A patent/AU2021225178B2/en active Active
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
-
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
-
2025
- 2025-04-28 AU AU2025202930A patent/AU2025202930A1/en active Pending
- 2025-09-12 JP JP2025152535A patent/JP2025186377A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3471780T1 (sl) | Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom | |
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| IL269371A (en) | Treatment methods | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| DK4050034T3 (da) | Cd3-bindende antistoffer | |
| EP3458034A4 (en) | POLYNUCLEOTIDES ENCODING RELAXIN | |
| IL256562A (en) | Humanized or chimeric cd3 antibodies | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| DK3474802T3 (da) | Medicinsk forbinding | |
| PL3612624T3 (pl) | Terapia genowa | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| SI3612237T1 (sl) | Genska terapija | |
| PL3978074T3 (pl) | Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1 | |
| EP3172897C0 (en) | ENCODER, DECODER AND METHOD | |
| IL259486A (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
| EP3925642C0 (en) | SYRINGE STABILIZER | |
| EP3630331C0 (en) | FLUID TREATMENT | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| BR112018002808A2 (pt) | Método de moldagem de materiais compostos, e materiais compostos | |
| KR20180084928A (ko) | 특히 전류의 도움으로 인간 케라틴 물질을 처리하기 위한 디바이스 | |
| EP3800199C0 (en) | H3.3 CTL PEPTIDES AND THEIR USES |